Dustin Chandler, a prominent advocate for medical cannabis in Alabama, is calling on state lawmakers to expedite the implementation of the medical cannabis program that was legalized in 2021. Chandler’s personal connection to the issue stems from his daughter Carly, who suffers from seizures. He has been a vocal supporter of cannabis-based treatments since 2014, when he helped push for Carly’s Law, which allowed for the use of CBD oil in the state.
Despite the legalization of medical marijuana, patients in Alabama have faced significant delays in accessing THC products due to unresolved legal disputes surrounding the licensing process. Chandler highlighted that, after 1,435 days since the law’s passage, patients still lack access to essential medications that could alleviate their medical conditions.
Chandler emphasizes the need for both CBD and THC to effectively manage seizure disorders. He noted that while CBD can be beneficial, sometimes a combination with THC is necessary for optimal seizure control. “Doctors treating epilepsy have indicated that THC can be an important part of the treatment plan for some patients,” he stated.
A major concern for Chandler is the Alabama Medical Cannabis Commission, which he accuses of failing to properly inspect facilities before granting licenses. He expressed disbelief that companies could receive licenses without proving their ability to provide cannabis products responsibly. “It raises serious questions about the capability of these companies to deliver the product to those in need,” Chandler remarked.
Additionally, Chandler pointed out that the commission has yet to create a patient registry, which is mandated by law. This registry is crucial for identifying eligible patients and ensuring they have access to licensed physicians who can recommend THC treatment. Without it, he worries that many patients are left without the necessary support to obtain their medication.
In an effort to spur action, Chandler has written to all 35 Alabama state senators, urging them to prioritize the implementation of the medical cannabis program. In his letter, he highlighted the urgency of the situation, stating, “Patients in Alabama, including my daughter, are still without access to the vital medication that could significantly improve their quality of life.”
Chandler’s letter emphasized that the lack of a patient registry and available products represents a failure to follow through on the promises made when the law was signed. He argued that the delay is not just an administrative issue; it is a denial of essential healthcare for those suffering from qualifying medical conditions.
To date, the Alabama Medical Cannabis Commission has reportedly spent over $7 million in taxpayer funds between Fiscal Year 2022 and November 2024, raising further concerns about accountability and transparency. As of now, the commission has not issued any statements addressing these issues in response to inquiries from local news outlets.
Chandler continues to advocate for immediate legislative action, stating that the time for change is critical. “Our loved ones cannot wait any longer for the relief that medical cannabis can provide,” he urged. His ongoing fight reflects the broader struggle many families face in accessing medical cannabis in Alabama, as they seek to hold lawmakers accountable for the implementation of a program that has been delayed for far too long.
English 
Spanish 
German 
Czech